| Mr Jeffrey C Mayo, RPH | |
|
713 5th St, Clay Center, KS 67432-2936 | |
| (785) 632-3121 | |
| (785) 632-2440 |
| Full Name | Mr Jeffrey C Mayo |
|---|---|
| Gender | Male |
| Speciality | Pharmacist |
| Location | 713 5th St, Clay Center, Kansas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1952739583 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 1-11226 (Kansas) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mr Jeffrey C Mayo, RPH 713 5th St, Clay Center, KS 67432-2936 Ph: (785) 632-3121 | Mr Jeffrey C Mayo, RPH 713 5th St, Clay Center, KS 67432-2936 Ph: (785) 632-3121 |
News Archive
On the eve of a new year, as millions of Americans struggle to find more meaning in their lives, Vulcan Productions and NOVA/WGBH have teamed up with Harvard psychologist and best-selling author of Stumbling on Happiness, Professor Daniel Gilbert, to produce This Emotional Life. This three-part documentary premieres on PBS January 4-6, 2010 (at 9:00 p.m. check local listings) and examines why people find happiness to be such an elusive goal.
Building on its worldwide reputation as a leader in neuroscience research, McGill University today joined with two leading Swiss research institutions - the University of Zurich (UZH) and the Swiss Federal Institute of Technology (ETHZ) - to enhance neuroscience research in a host of areas, in fields that include pain therapy, Alzheimer's disease, synapse modelling and repair, neuroimmunology and genetic mechanisms of brain diseases.
Barr Pharmaceuticals, Inc. has announced that its subsidiary, Barr Laboratories, Inc., has received final approval from the U.S. Food and Drug Administration (FDA) for its generic version of Boehringer Ingelheim Pharmaceuticals, Inc.'s Mirapex Tablets (Pramipexole Dihydrochloride) 0.125mg, 0.25mg, 0.5mg, 1mg & 1.5mg.
Valeant Pharmaceuticals International, Inc. today announced that that its wholly owned subsidiary, Valeant Pharmaceuticals North America LLC, received notice that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Jublia® (efinaconazole 10% topical solution), the first topical triazole approved for the treatment of onychomycosis of the toenails.
Researchers from Flinders University and the Robinson Research Institute at the University of Adelaide have identified distinctive biological markers that could improve the routine blood tests pregnant women already undergo and detect risks for pregnancy complications earlier than currently possible.
› Verified 4 days ago
Scott Nolan Patterson, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 422 Lincoln Ave, Clay Center, KS 67432 Phone: 785-632-3115 Fax: 785-632-3777 | |
Mrs. Carrie A Lane, R.PH. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 708 Liberty St, Clay Center, KS 67432 Phone: 785-632-3032 Fax: 785-632-5943 | |
Ms. Laura Sue Squires, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 422 Lincoln Ave, Clay Center, KS 67432 Phone: 785-632-3115 Fax: 785-632-3777 | |
Dr. Sue Ann Hamon, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 422 Lincoln Ave, Clay Center, KS 67432 Phone: 785-632-3115 | |
Ashlee Rickabaugh, PHARMD, MBA Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 422 Lincoln Ave, Clay Center, KS 67432 Phone: 785-632-3115 | |
Roxanna Lynn Martin, R.PH. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 708 Liberty St, Clay Center, KS 67432 Phone: 785-632-3032 Fax: 785-632-5943 |